Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8629128 | MAYNE PHARMA | Vitamin formulation |
May, 2026
(2 years from now) | |
US8263580 | MAYNE PHARMA | Vitamin formulation |
May, 2028
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Nov 5, 2022 |
Market Authorisation Date: 06 October, 2010
Treatment: Use of a calcipotriene containing foam for the treatment of psoriasis; Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 18 years and older; Use of calcipotriene...
Dosage: AEROSOL, FOAM;TOPICAL